Brinsupri Launch Gives Insmed A New Respiratory Revenue Pillar

Simply Wall St.03-19 10:12

Insmed (NasdaqGS:INSM) has launched Brinsupri, also known as brensocatib, for non cystic fibrosis bronchiectasis. Brinsupri is the first approved therapy for this condition and has already generated ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620218868?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-19 10:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620218868","market":"nz","top_or_hot":-1,"title":"Brinsupri Launch Gives Insmed A New Respiratory Revenue Pillar","media":"Simply Wall St.","content":"<div>\n<p>Insmed (NasdaqGS:INSM) has launched Brinsupri, also known as brensocatib, for non cystic fibrosis bronchiectasis. Brinsupri is the first approved therapy for this condition and has already generated ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-insm/insmed/news/brinsupri-launch-gives-insmed-a-new-respiratory-revenue-pill\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Brinsupri Launch Gives Insmed A New Respiratory Revenue Pillar</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBrinsupri Launch Gives Insmed A New Respiratory Revenue Pillar\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-19 10:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-insm/insmed/news/brinsupri-launch-gives-insmed-a-new-respiratory-revenue-pill><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Insmed (NasdaqGS:INSM) has launched Brinsupri, also known as brensocatib, for non cystic fibrosis bronchiectasis. Brinsupri is the first approved therapy for this condition and has already generated ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-insm/insmed/news/brinsupri-launch-gives-insmed-a-new-respiratory-revenue-pill\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INSM","symbol_name":"Insmed","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-insm/insmed/news/brinsupri-launch-gives-insmed-a-new-respiratory-revenue-pill","article_id":"2620218868","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-insm/insmed/news/brinsupri-launch-gives-insmed-a-new-respiratory-revenue-pill","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620218868","pubTimestamp":1773886344,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Insmed (NasdaqGS:INSM) has launched Brinsupri, also known as brensocatib, for non cystic fibrosis bronchiectasis.\nBrinsupri is the first approved therapy for this condition and has already generated significant initial sales.\nThe successful launch marks a material commercial milestone for Insmed and adds a new revenue stream alongside its existing portfolio.\n\nInsmed focuses on treatments for serious and rare respiratory diseases, so the approval and rollout of Brinsupri fit directly into its...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"INSM":"Insmed"},"translate_title":"Brinsupri的推出为Insmed带来了新的呼吸收入支柱","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":1.5},"content_text":"Insmed (NasdaqGS:INSM) has launched Brinsupri, also known as brensocatib, for non cystic fibrosis bronchiectasis. Brinsupri is the first approved therapy for this condition and has already generated significant initial sales. The successful launch marks a material commercial milestone for Insmed and adds a new revenue stream alongside its existing portfolio.  Insmed focuses on treatments for serious and rare respiratory diseases, so the approval and rollout of Brinsupri fit directly into its core business. Having the first approved therapy for non cystic fibrosis bronchiectasis may help the company deepen its presence in this niche, where patients previously had limited targeted options. For investors tracking NasdaqGS:INSM, the early commercial traction of Brinsupri gives fresh information that goes beyond recent discussions about valuation and share price moves. The way this new product beds in over time, including physician uptake and real world use, could become an important factor in how the business develops from here. Stay updated on the most important news stories for Insmed by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Insmed. NasdaqGS:INSM Earnings & Revenue Growth as at Mar 2026 We've flagged 2 risks for Insmed. See which could impact your investment. The Brinsupri launch gives Insmed a new commercial pillar that sits alongside its existing respiratory portfolio and broader pipeline in immunology, inflammation, neurology, and rare diseases. Initial Brinsupri sales of US$28 million show there is real patient demand in non cystic fibrosis bronchiectasis, a setting where there was no approved therapy before. For a company still investing heavily in R&D and not yet profitable, adding a fresh revenue source in an area that closely matches its respiratory focus can help support ongoing development work. The launch has also helped Insmed stand out in small cap portfolios, even though some investors such as Artisan Partners have exited because Insmed has grown beyond their mandate rather than due to a change in their view of the business. AdvertisementHow This Fits Into The Insmed Narrative  The Brinsupri launch directly supports prior expectations that respiratory assets could provide new revenue streams and help fund future platform expansion. Early traction raises the bar for execution. Any slower than expected physician adoption or access hurdles could challenge earlier assumptions about how quickly the product would contribute. The initial sales figure and real world uptake patterns may not have been fully reflected in earlier revenue scenarios that focused more on pre launch guidance and pipeline catalysts.  Knowing what a company is worth starts with understanding its story.\n Check out one of the top narratives in the Simply Wall St Community for Insmed to help decide what it's worth to you. The Risks and Rewards Investors Should Consider  ⚠️ Shareholders have been diluted in the past year, which is a reminder that further capital raising is a possibility for a company investing heavily in growth. ⚠️ Significant insider selling over the past 3 months may concern some investors who track management trading activity as a sentiment signal. 🎁 Earnings are forecast to grow 63.2% per year, which highlights how sensitive the story is to successful execution across Brinsupri and the rest of the portfolio. 🎁 Analysts are in good agreement that the stock price will rise by 49.3%, reflecting generally constructive sentiment on Insmed's commercial assets and pipeline.  What To Watch Going Forward From here, focus on how Brinsupri usage trends across different treatment centers, how quickly payers define and implement reimbursement criteria, and whether real world outcomes support continued uptake. Monitor any updates to guidance that tie Brinsupri to Insmed's total revenue mix, as well as commentary on international launches and label developments across the rest of the pipeline. Investors may also want to watch how peers in respiratory and rare disease such as Vertex Pharmaceuticals, Regeneron, and AstraZeneca talk about bronchiectasis and related respiratory segments, because their activity can shape physician behavior and payer expectations. To stay updated on how the latest news affects the investment narrative for Insmed, visit the\n community page for Insmed to follow the top community narratives.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620218868","isCrawlerRequest":true}